{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype",
      "version": "1.0.0",
      "authors": "Esther Wollert",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/7e4be528f12abd28be768b62402fba6e083eaf9e/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/walsh2008.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "epibatidine",
      "id": "8fa881896eaa3aadba5ff12130ddcc6eca42fcf2a2ca6719d07a59368a7601b74b796b0b98a3a97fa9640738e47eb39041cf058f925b984f219a2086c67502cf"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotine",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "alpha-3 beta-2 nAChR",
      "id": "a4cd09a67ef2fe71c099077da07563a154883751c9700eb7b1f95b980edf88d1788487685657f5f7942661125912a6d2f4a86e75d9561b56ae73bd4a5363f442"
    },
    {
      "function": "Abundance",
      "namespace": "HBP",
      "name": "alpha-4 beta-2 nAChR",
      "id": "a9b7c683882f97e9a781f82541ce483ce9d7ed6adcca7af1876821e91eb3b587dd80ed1ee838df6881ff8e46fbe98c6bd66231f3476dfddc0b944dfd4ba89aa6"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "alpha6beta2 nicotinic acetylcholine receptor",
      "id": "f5007132f708e0376c58bee4b0fdee8c6047d5576461a672294af7660c2c0b2e7def992e3d00d8035257d2fbc53034f67715d21e4437ee9c07f1ed350ef8d5d1"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "epibatidine",
          "id": "8fa881896eaa3aadba5ff12130ddcc6eca42fcf2a2ca6719d07a59368a7601b74b796b0b98a3a97fa9640738e47eb39041cf058f925b984f219a2086c67502cf"
        },
        {
          "function": "Abundance",
          "namespace": "HBP",
          "name": "alpha-3 beta-2 nAChR",
          "id": "a4cd09a67ef2fe71c099077da07563a154883751c9700eb7b1f95b980edf88d1788487685657f5f7942661125912a6d2f4a86e75d9561b56ae73bd4a5363f442"
        }
      ],
      "id": "bda1172098853ab7356e15f2e8569064c75fa49614a87746437a62bce0e29a3293837e92b1ad6253ce162b1e9751e6b07cbb0b6ec60759f2ba32f69ef2f7fbb5"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "epibatidine",
          "id": "8fa881896eaa3aadba5ff12130ddcc6eca42fcf2a2ca6719d07a59368a7601b74b796b0b98a3a97fa9640738e47eb39041cf058f925b984f219a2086c67502cf"
        },
        {
          "function": "Abundance",
          "namespace": "HBP",
          "name": "alpha-4 beta-2 nAChR",
          "id": "a9b7c683882f97e9a781f82541ce483ce9d7ed6adcca7af1876821e91eb3b587dd80ed1ee838df6881ff8e46fbe98c6bd66231f3476dfddc0b944dfd4ba89aa6"
        }
      ],
      "id": "673e9f9efeca0da516d085edae94f23071f07f5d3c2d5b823bfc51d99ce20ff11ed93869742542e9dfaf981f4381c4db2a6c3bc904479c86f2b19dc15bc7cfc6"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "epibatidine",
          "id": "8fa881896eaa3aadba5ff12130ddcc6eca42fcf2a2ca6719d07a59368a7601b74b796b0b98a3a97fa9640738e47eb39041cf058f925b984f219a2086c67502cf"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "alpha6beta2 nicotinic acetylcholine receptor",
          "id": "f5007132f708e0376c58bee4b0fdee8c6047d5576461a672294af7660c2c0b2e7def992e3d00d8035257d2fbc53034f67715d21e4437ee9c07f1ed350ef8d5d1"
        }
      ],
      "id": "754f70dcb1d142317baa0eb45920af402ff09b513ae95f7d783f581eaa98f74c898445fba276549fd52a6c8c10deff366aecc64603cd632aaa8901cfecfe1459"
    }
  ],
  "links": [
    {
      "relation": "hasComponent",
      "source": 7,
      "target": 0,
      "key": "88b23a98cbe57ad6a8c98fe70cc083de5d6c5f96f6141bf8ebe706e350f6497c39543454823aea2eb785012d44a92ec94d16d3e6cae87e3078d908e726cabfea"
    },
    {
      "relation": "hasComponent",
      "source": 7,
      "target": 4,
      "key": "8428d73e3f7cf21a7e35295fac25b5bf717e5de28827e406e2a1c2a9d01ad0b2057298ae0a83b279bf8e85be476c5e61c515958ab2678a2664266be28bbd06de"
    },
    {
      "line": 85,
      "relation": "increases",
      "evidence": "We first assayed expression of a6b2 or a3b2 receptors by binding the agonist, 125 I-labeled epibatidine (Fig. 1, A and B), to stably transfected a6FLAGb2HA cells and transiently trans- fected a3FLAGb2HA cells.",
      "citation": {
        "type": "PubMed",
        "reference": "18174175"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 7,
      "target": 4,
      "key": "01967fb400313008994e88f1bbf5bb7483290dff1f0702956852264dda533f66cb9148c6ada8bb0e14db5fffe354f91dd48f857bcc3c294e35ef9c2b8826646a"
    },
    {
      "relation": "hasComponent",
      "source": 5,
      "target": 0,
      "key": "6cf645904a88c96a294c017127e071c0a0a3b6e44bf92202b7794af377ee4b434115bd15f8f61ceec1d3cb3284608616e7a56232cdc025f7d882222464c1c974"
    },
    {
      "relation": "hasComponent",
      "source": 5,
      "target": 2,
      "key": "8668e520af93c765bfdbde77a7ce84d5bf0dd178e7330dd00b20fd79e908d121e371641c95250c9dfd27bb63d715e4bdb5b634f0e2c1ec31f8a77bf941ca73c2"
    },
    {
      "line": 86,
      "relation": "increases",
      "evidence": "We first assayed expression of a6b2 or a3b2 receptors by binding the agonist, 125 I-labeled epibatidine (Fig. 1, A and B), to stably transfected a6FLAGb2HA cells and transiently trans- fected a3FLAGb2HA cells.",
      "citation": {
        "type": "PubMed",
        "reference": "18174175"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 5,
      "target": 2,
      "key": "c236c69501e92ab617353d5949331a2b72eba5c9a78e338f0102a887125ac378ee331bb1299784ba1ffac1be1be0bbfe3fdcf27cc824787c516441b6788ffcae"
    },
    {
      "relation": "hasComponent",
      "source": 6,
      "target": 0,
      "key": "473738905f9352d93e60e00548bd1dfc16c964d61604d3b4e8850d3c97b1a3e6fd16029c4e6285a31b5468e73af2719078e34e08793adc02dd3920dbb797a312"
    },
    {
      "relation": "hasComponent",
      "source": 6,
      "target": 3,
      "key": "ff99b49d019cfb6abee246d368818dad089435678d0c0d0b94baa6fd911ba119817ad253dd9be392e3e942226b309811adcccb68c6c00a4d99f2020bab497848"
    },
    {
      "line": 99,
      "relation": "increases",
      "evidence": "After nicotine treat- ment for 24 h at 30µM nicotine, 125 I-labeled epibatidine bind- ing to a6b2 receptors increased significantly at 37 and 30°C.",
      "citation": {
        "type": "PubMed",
        "reference": "18174175"
      },
      "source": 1,
      "target": 4,
      "key": "0a37860e5dc0eb862873af9977b24e5cba756935376f168ff8c37a79569db3c45366f6823847df4bac117bfd4852a959fbddcdcbdc86e8ebd367aacecc706133"
    },
    {
      "line": 104,
      "relation": "increases",
      "evidence": " This range is broader but similar to what was observed for a4b2 where the -fold increase after nicotine treat- ment varied 3–6-fold (29).",
      "citation": {
        "type": "PubMed",
        "reference": "18174175"
      },
      "source": 1,
      "target": 3,
      "key": "7a9d24e320d83889bc771c850d170d6d19ae3d8ce59249c7b66894f2244a80d75cc314569b7b99dbcfe245631baa4d4dd4eea70af8015c94ead1eed475f6c356"
    },
    {
      "line": 109,
      "relation": "increases",
      "evidence": "At 37°C, the timecourse of the a6b2 and a3b2 up-regulation is essentially complete after 2 h, and no signifi- cant changes were observed with longer nicotine incubations.",
      "citation": {
        "type": "PubMed",
        "reference": "18174175"
      },
      "source": 1,
      "target": 2,
      "key": "a9910c51af40beed3a3005ab3da09430e3a0f730d356675a40a89f457f6f92c5634d739c9680b6f27c895c05f2461c26f02ea2277a1fdbbf5258ba1fbf4be051"
    }
  ]
}